Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Benitec Biopharma has reported Operating Expenses for 7 years, with the latest figure at $13.4 million in Q4 2025.

• Quarterly Operating Expenses rose 23.8% year-over-year to $13.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $48.3 million (up 83.94% YoY) and the FY2025 annual result came in at $41.8 million, up 85.7% from the prior year.
• Operating Expenses improved to $13.4 million in Q4 2025 per BNTC's latest filing, from $9.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $15.3 million in Q1 2025 and troughed at $3.5 million in Q1 2022.
• A 5-year average of $6.6 million and a median of $5.2 million in 2021 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses fell 7.54% in 2022, then soared 270.32% in 2025.
• Over 5 years, Operating Expenses stood at $4.9 million in 2021, then climbed by 15.72% to $5.6 million in 2022, then grew by 23.17% to $6.9 million in 2023, then jumped by 55.98% to $10.8 million in 2024, then rose by 23.8% to $13.4 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $13.4 million, $9.8 million, and $9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.